{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:31:29Z","timestamp":1793035889223,"version":"4.5.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P60AR 47785"],"award-info":[{"award-number":["P60AR 47785"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["K24AR070892"],"award-info":[{"award-number":["K24AR070892"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1053\/j.ajkd.2017.01.055","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T21:15:43Z","timestamp":1493241343000},"page":"422-439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":199,"title":["Management of Gout and Hyperuricemia in CKD"],"prefix":"10.1053","volume":"70","author":[{"given":"Ana Beatriz","family":"Vargas-Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuhina","family":"Neogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2017.01.055_bib1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence and risk factors","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib2","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"suppl 2","key":"10.1053\/j.ajkd.2017.01.055_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1185\/03007995.2015.1087979","article-title":"Why focus on uric acid?","volume":"31","author":"Johnson","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1053\/j.ajkd.2017.01.055_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","article-title":"Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies","volume":"17","author":"Roughley","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1053\/j.ajkd.2017.01.055_bib5","doi-asserted-by":"crossref","first-page":"e50046","DOI":"10.1371\/journal.pone.0050046","article-title":"Reduced glomerular function and prevalence of gout: NHANES 2009-10","volume":"7","author":"Krishnan","year":"2012","journal-title":"PLoS One"},{"key":"10.1053\/j.ajkd.2017.01.055_bib6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am J Med"},{"key":"10.1053\/j.ajkd.2017.01.055_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12882-015-0189-z","article-title":"The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study","volume":"16","author":"Fraser","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib8","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","article-title":"Gout","volume":"388","author":"Dalbeth","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2017.01.055_bib9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMcp1001124","article-title":"Clinical practice. Gout","volume":"364","author":"Neogi","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2017.01.055_bib10","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/ard.2009.109884","article-title":"Menopause, postmenopausal hormone use and risk of incident gout","volume":"69","author":"Hak","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"suppl 10","key":"10.1053\/j.ajkd.2017.01.055_bib11","article-title":"Patterns of joint involvement in gout flares","volume":"68","author":"Vargas-Santos","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib12","first-page":"2186","article-title":"Female gout: clinical and laboratory features","volume":"32","author":"De Souza","year":"2005","journal-title":"J\u00a0Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.semarthrit.2012.03.007","article-title":"The broad spectrum of urate crystal deposition: unusual presentations of gouty tophi","volume":"42","author":"Forbess","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2017.01.055_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00296-007-0421-7","article-title":"Elderly-onset gout: a review","volume":"28","author":"De Leonardis","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1053\/j.ajkd.2017.01.055_bib15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/BOR.0000000000000246","article-title":"Calcium pyrophosphate deposition disease: a review of epidemiologic findings","volume":"28","author":"Abhishek","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib16","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib17","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/art.39254","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"67","author":"Neogi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib18","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1053\/j.ajkd.2017.01.055_bib19","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1053\/j.ajkd.2017.01.055_bib20","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib21","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1053\/j.ajkd.2017.01.055_bib22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/annrheumdis-2013-203325","article-title":"Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative","volume":"73","author":"Sivera","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib23","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199602153340707","article-title":"The management of gout","volume":"334","author":"Emmerson","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2017.01.055_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RHU.0b013e318204a8f9","article-title":"The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach","volume":"17","author":"Lindsay","year":"2011","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib25","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","article-title":"Gout: why is this curable disease so seldom cured?","volume":"71","author":"Doherty","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","article-title":"Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events","volume":"20","author":"Dalbeth","year":"2007","journal-title":"Semin Dial"},{"key":"10.1053\/j.ajkd.2017.01.055_bib27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00228-016-2133-y","article-title":"A\u00a0population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis","volume":"73","author":"Wright","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10157-012-0763-7","article-title":"Febuxostat for hyperuricemia: experience with patients on chronic hemodialysis treatment","volume":"17","author":"Horikoshi","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4137\/DTI.S16524","article-title":"Febuxostat for hyperuricemia in patients with advanced chronic kidney disease","volume":"8","author":"Akimoto","year":"2014","journal-title":"Drug Target Insights"},{"key":"10.1053\/j.ajkd.2017.01.055_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40780-015-0028-1","article-title":"Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients","volume":"1","author":"Mitsuboshi","year":"2015","journal-title":"J\u00a0Pharm Health Care Sci"},{"key":"10.1053\/j.ajkd.2017.01.055_bib31","first-page":"9106935","article-title":"Febuxostat and increased dialysis as a treatment for severe tophaceous gout in a hemodialysis patient","volume":"2016","author":"Frassetto","year":"2016","journal-title":"Case Rep Nephrol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib32","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1053\/j.ajkd.2016.07.001","article-title":"Febuxostat in hyperuricemic patients with advanced CKD","volume":"68","author":"Lim","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.5414\/CN108481","article-title":"Pharmacokinetics and pharmacodynamics of pegloticase in patients with end-stage renal failure receiving hemodialysis","volume":"83","author":"Bleyer","year":"2015","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib34","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/art.20781","article-title":"Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial","volume":"52","author":"Garg","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2017.01.055_bib35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2169\/internalmedicine.48.1817","article-title":"Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients","volume":"48","author":"Ohno","year":"2009","journal-title":"Intern Med"},{"key":"10.1053\/j.ajkd.2017.01.055_bib36","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2169\/internalmedicine.44.706","article-title":"Frequency of gouty arthritis in patients with end-stage renal disease in Japan","volume":"44","author":"Ohno","year":"2005","journal-title":"Intern Med"},{"key":"10.1053\/j.ajkd.2017.01.055_bib37","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0272-6386(12)80995-4","article-title":"Gouty arthritis in end-stage renal disease: clinical course and rarity of new cases","volume":"23","author":"Ifudu","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/RHU.0000000000000235","article-title":"Does starting allopurinol prolong acute treated gout? A randomized clinical trial","volume":"21","author":"Hill","year":"2015","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib39","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.amjmed.2012.05.025","article-title":"Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial","volume":"125","author":"Taylor","year":"2012","journal-title":"Am J Med"},{"key":"10.1053\/j.ajkd.2017.01.055_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1053\/j.ajkd.2017.01.055_bib41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrrheum.2014.32","article-title":"Optimizing current treatment of gout","volume":"10","author":"Rees","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib42","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","article-title":"Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study","volume":"72","author":"Rees","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib43","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib44","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A\u00a0randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg\/day versus benzbromarone 100-200 mg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib45","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2017.01.055_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrrheum.2015.132","article-title":"Allopurinol hypersensitivity: investigating the cause and minimizing the risk","volume":"12","author":"Stamp","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib47","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/RHU.0b013e31829372e6","article-title":"Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol","volume":"19","author":"Paisansinsup","year":"2013","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib48","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2017.01.055_bib49","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/cea.12184","article-title":"Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response","volume":"43","author":"Yun","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1053\/j.ajkd.2017.01.055_bib50","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"10.1053\/j.ajkd.2017.01.055_bib51","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/acr.21817","article-title":"Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1053\/j.ajkd.2017.01.055_bib52","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumd00512-0096","article-title":"Allopurinol in gouty nephropathy and renal dialysis","volume":"25","author":"Rundles","year":"1966","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib53","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00002480-196504000-00047","article-title":"The use of allopurinol (HPP) to control hyperuricemia in patients on chronic intermittent hemodialysis","volume":"11","author":"Hayes","year":"1965","journal-title":"Trans Am Soc Artif Intern Organs"},{"key":"10.1053\/j.ajkd.2017.01.055_bib54","first-page":"2012","article-title":"Successful use of allopurinol in a patient on dialysis","author":"Day","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1053\/j.ajkd.2017.01.055_bib55","first-page":"1039","article-title":"The effect of allopurinol on lowering blood pressure in hemodialysis patients with hyperuricemia","volume":"17","author":"Jalalzadeh","year":"2012","journal-title":"J\u00a0Res Med Sci"},{"key":"10.1053\/j.ajkd.2017.01.055_bib56","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2017.01.055_bib57","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2017.01.055_bib58","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib59","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1053\/j.ajkd.2017.01.055_bib60","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/art.39654","article-title":"Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment","volume":"68","author":"Saag","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib61","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/DDDT.S56597","article-title":"Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients","volume":"8","author":"Sofue","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1053\/j.ajkd.2017.01.055_bib62","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.transproceed.2013.09.045","article-title":"Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients","volume":"46","author":"Tojimbara","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1053\/j.ajkd.2017.01.055_bib63","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/jcpt.12322","article-title":"Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"40","author":"Chou","year":"2015","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1053\/j.ajkd.2017.01.055_bib64","first-page":"153","article-title":"Toxic epidermal necrolysis and severe hypersensitivity reactions added to the EU SPC","volume":"24","year":"2015","journal-title":"Prescrire Int"},{"key":"10.1053\/j.ajkd.2017.01.055_bib65","unstructured":"Health Canada. Summary safety review - ULORIC (febuxostat) - assessing a possible risk of drug reaction\/rash with eosinophilia and\u00a0systemic symptoms (DRESS). http:\/\/www.hc-sc.gc.ca\/dhp-mps\/medeff\/reviews-examens\/uloric3-eng.php. Accessed August 4, 2016."},{"key":"10.1053\/j.ajkd.2017.01.055_bib66","unstructured":"European Medicines Agency. Adenuric: EPAR - product information (last updated: February 5, 2016). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000777\/WC500021812.pdf. Accessed August 04,\u00a02016."},{"key":"10.1053\/j.ajkd.2017.01.055_bib67","first-page":"251","article-title":"Febuxostat hypersensitivity: another cause of DRESS syndrome in chronic kidney disease?","volume":"48","author":"Paschou","year":"2016","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib68","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.semarthrit.2012.11.002","article-title":"Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database","volume":"42","author":"Gandhi","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2017.01.055_bib69","unstructured":"Health Canada. Summary safety review - ULORIC (febuxostat) - assessing the potential risk of heart failure. http:\/\/www.hc-sc.gc.ca\/dhp-mps\/medeff\/reviews-examens\/uloric2-eng.php. Accessed August 4,\u00a02016."},{"key":"10.1053\/j.ajkd.2017.01.055_bib70","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ahj.2012.04.011","article-title":"Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities","volume":"164","author":"White","year":"2012","journal-title":"Am Heart J"},{"key":"10.1053\/j.ajkd.2017.01.055_bib71","doi-asserted-by":"crossref","first-page":"e005354","DOI":"10.1136\/bmjopen-2014-005354","article-title":"Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia","volume":"4","author":"MacDonald","year":"2014","journal-title":"BMJ Open"},{"key":"10.1053\/j.ajkd.2017.01.055_bib72","first-page":"326","article-title":"Cost comparison of urate-lowering therapies in patients with gout and moderate-to-severe chronic kidney disease","volume":"22","author":"Mitri","year":"2016","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1053\/j.ajkd.2017.01.055_bib73","first-page":"265","article-title":"Febuxostat in the management of gout: a cost-effectiveness analysis","volume":"19","author":"Smolen","year":"2016","journal-title":"J\u00a0Med Econ"},{"key":"10.1053\/j.ajkd.2017.01.055_bib74","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10198-014-0617-1","article-title":"Cost-effectiveness of febuxostat in chronic gout","volume":"15","author":"Beard","year":"2014","journal-title":"Eur J Health Econ"},{"key":"10.1053\/j.ajkd.2017.01.055_bib75","first-page":"165","article-title":"Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective","volume":"21","author":"Gandhi","year":"2015","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1053\/j.ajkd.2017.01.055_bib76","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.semarthrit.2013.05.004","article-title":"A\u00a0systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout","volume":"43","author":"Faruque","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1053\/j.ajkd.2017.01.055_bib77","first-page":"CD010457","article-title":"Uricosuric medications for chronic gout","author":"Kydd","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.ajkd.2017.01.055_bib78","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2017.01.055_bib79","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1136\/annrheumdis-2012-201795","article-title":"Long-term safety of pegloticase in chronic gout refractory to conventional treatment","volume":"72","author":"Becker","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib80","unstructured":"Food and Drug Adminitration. Colcrys full prescribing information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022352s022lbl.pdf. Accessed November 27,\u00a02016."},{"key":"10.1053\/j.ajkd.2017.01.055_bib81","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/art.27667","article-title":"Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC\/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis","volume":"62","author":"Joosten","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2017.01.055_bib82","doi-asserted-by":"crossref","first-page":"ITC1","DOI":"10.7326\/AITC201607050","article-title":"Gout","volume":"165","author":"Neogi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2017.01.055_bib83","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/BOR.0000000000000143","article-title":"Interleukin-1 as a therapeutic target in gout","volume":"27","author":"Dumusc","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib84","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11926-013-0398-z","article-title":"Anti-interleukin-1 therapy in the management of gout","volume":"16","author":"Schlesinger","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"10.1053\/j.ajkd.2017.01.055_bib85","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/phar.1265","article-title":"Role of interleukin-1 inhibitors in the management of gout","volume":"33","author":"Tran","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.ajkd.2017.01.055_bib86","first-page":"331","article-title":"Local ice therapy during bouts of acute gouty arthritis","volume":"29","author":"Schlesinger","year":"2002","journal-title":"J\u00a0Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib87","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jbspin.2006.03.006","article-title":"Colchicine today","volume":"73","author":"Niel","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.1053\/j.ajkd.2017.01.055_bib88","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2017.01.055_bib89","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1056\/NEJMp1003126","article-title":"Incentives for drug development\u2013the curious case of colchicine","volume":"362","author":"Kesselheim","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2017.01.055_bib90","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/431592","article-title":"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study","volume":"41","author":"Hung","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib91","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1345\/aph.1H064","article-title":"Rhabdomyolysis in a patient treated with colchicine and atorvastatin","volume":"40","author":"Tufan","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1053\/j.ajkd.2017.01.055_bib92","unstructured":"PL Detail-Document, Clinically Significant Statin Drug Interactions. Pharmacist\u2019s Letter\/Prescriber\u2019s Letter. March 2016. http:\/\/pharmacistsletter.therapeuticresearch.com\/pl\/ArticleDD.aspx?nidchk=1&cs=&s=PL&pt=2&fpt=31&dd=280606&pb=PL&cat=4803&segment=4421."},{"key":"10.1053\/j.ajkd.2017.01.055_bib93","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/art.33369","article-title":"Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal","volume":"64","author":"Neogi","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2017.01.055_bib94","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/j.1523-1755.2005.00273.x","article-title":"Hyperuricemia induces endothelial dysfunction","volume":"67","author":"Khosla","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2017.01.055_bib95","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/HJH.0b013e328337da1d","article-title":"Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction","volume":"28","author":"Yu","year":"2010","journal-title":"J\u00a0Hypertens"},{"key":"10.1053\/j.ajkd.2017.01.055_bib96","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/hy1101.092839","article-title":"Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism","volume":"38","author":"Mazzali","year":"2001","journal-title":"Hypertension"},{"key":"10.1053\/j.ajkd.2017.01.055_bib97","doi-asserted-by":"crossref","first-page":"F991","DOI":"10.1152\/ajprenal.00283.2001","article-title":"Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism","volume":"282","author":"Mazzali","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib98","doi-asserted-by":"crossref","first-page":"F1105","DOI":"10.1152\/ajprenal.00170.2002","article-title":"Mild hyperuricemia induces glomerular hypertension in normal rats","volume":"283","author":"Sanchez-Lozada","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib99","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000066303","article-title":"Hyperuricemia causes glomerular hypertrophy in the rat","volume":"23","author":"Nakagawa","year":"2003","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00074.x","article-title":"Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats","volume":"67","author":"Sanchez-Lozada","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2017.01.055_bib101","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ndt\/gfm783","article-title":"Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia","volume":"23","author":"Sanchez-Lozada","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2017.01.055_bib102","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1159\/000330274","article-title":"Use of uric acid-lowering agents limits experimental cyclosporine nephropathy","volume":"120","author":"Mazali","year":"2012","journal-title":"Nephron Exp Nephrol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib103","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1291\/hypres.24.691","article-title":"Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects","volume":"24","author":"Iseki","year":"2001","journal-title":"Hypertens Res"},{"key":"10.1053\/j.ajkd.2017.01.055_bib104","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","article-title":"Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort","volume":"44","author":"Iseki","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib105","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1681\/ASN.2004030208","article-title":"Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study","volume":"16","author":"Domrongkitchaiporn","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib106","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.ajkd.2007.05.013","article-title":"Relationship of uric acid with progression of kidney disease","volume":"50","author":"Chonchol","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib107","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1681\/ASN.2008010080","article-title":"Elevated uric acid increases the risk for kidney disease","volume":"19","author":"Obermayr","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib108","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1681\/ASN.2007101075","article-title":"Uric acid and incident kidney disease in the community","volume":"19","author":"Weiner","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib109","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/archinternmed.2008.605","article-title":"Risk factors for end-stage renal disease: 25-year follow-up","volume":"169","author":"Hsu","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.ajkd.2017.01.055_bib110","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3899\/jrheum.081199","article-title":"Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate","volume":"36","author":"See","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib111","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/j.ajkd.2010.01.019","article-title":"Association of uric acid with change in kidney function in healthy normotensive individuals","volume":"56","author":"Bellomo","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib112","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1093\/ndt\/gfq740","article-title":"Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study","volume":"26","author":"Ben-Dov","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2017.01.055_bib113","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MAJ.0b013e318218bd89","article-title":"Elevated serum uric acid predicts chronic kidney disease","volume":"342","author":"Yamada","year":"2011","journal-title":"Am J Med Sci"},{"key":"10.1053\/j.ajkd.2017.01.055_bib114","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1161\/HYPERTENSIONAHA.113.00859","article-title":"Serum uric acid level, longitudinal blood pressure, renal function, and long-term mortality in treated hypertensive patients","volume":"62","author":"Dawson","year":"2013","journal-title":"Hypertension"},{"key":"10.1053\/j.ajkd.2017.01.055_bib115","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/hr.2013.11","article-title":"Changes in serum uric acid have a reciprocal effect on eGFR change: a 10-year follow-up study of community-based screening in Okinawa","volume":"36","author":"Iseki","year":"2013","journal-title":"Japan. Hypertens Res"},{"key":"10.1053\/j.ajkd.2017.01.055_bib116","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3899\/jrheum.131159","article-title":"Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia","volume":"41","author":"Levy","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib117","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1053\/j.ajkd.2015.06.015","article-title":"Hyperuricemia and progression of CKD in children and adolescents: the Chronic Kidney Disease in Children (CKiD) Cohort Study","volume":"66","author":"Rodenbach","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib118","doi-asserted-by":"crossref","first-page":"e0145506","DOI":"10.1371\/journal.pone.0145506","article-title":"Targeting uric acid and the inhibition of progression to end-stage renal disease\u2013a propensity score analysis","volume":"10","author":"Uchida","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.ajkd.2017.01.055_bib119","doi-asserted-by":"crossref","first-page":"e0129797","DOI":"10.1371\/journal.pone.0129797","article-title":"Uric acid is independently associated with diabetic kidney disease: a cross-sectional study in a Chinese population","volume":"10","author":"Yan","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.ajkd.2017.01.055_bib120","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/dmrr.2768","article-title":"Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus-a 4.6-year cohort study","volume":"32","author":"Chang","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1053\/j.ajkd.2017.01.055_bib121","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/ki.1997.260","article-title":"Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study","volume":"51","author":"Hunsicker","year":"1997","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2017.01.055_bib122","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1053\/j.ajkd.2007.10.035","article-title":"The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD","volume":"51","author":"Weiner","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib123","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.exger.2008.01.006","article-title":"Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study","volume":"43","author":"Sturm","year":"2008","journal-title":"Exp Gerontol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib124","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1053\/j.ajkd.2008.12.021","article-title":"Uric acid and long-term outcomes in CKD","volume":"53","author":"Madero","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib125","doi-asserted-by":"crossref","first-page":"e0132927","DOI":"10.1371\/journal.pone.0132927","article-title":"Predictors and the subsequent risk of end-stage renal disease - usefulness of 30% decline in estimated GFR over 2 years","volume":"10","author":"Chang","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.ajkd.2017.01.055_bib126","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s10157-015-1120-4","article-title":"Serum uric acid and the incidence of CKD and hypertension","volume":"19","author":"Kuriyama","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib127","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/RHU.0b013e318204aab4","article-title":"Renal function in gout: long-term treatment effects of febuxostat","volume":"17","author":"Whelton","year":"2011","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib128","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4103\/0971-4065.114499","article-title":"Allopurinol for prevention of progression of kidney disease with hyperuricemia","volume":"23","author":"Pai","year":"2013","journal-title":"Indian J Nephrol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib129","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3810\/pgm.2013.01.2626","article-title":"Preservation of renal function during gout treatment with febuxostat: a quantitative study","volume":"125","author":"Whelton","year":"2013","journal-title":"Postgrad Med"},{"key":"10.1053\/j.ajkd.2017.01.055_bib130","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/hr.2014.107","article-title":"Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction","volume":"37","author":"Shibagaki","year":"2014","journal-title":"Hypertens Res"},{"key":"10.1053\/j.ajkd.2017.01.055_bib131","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.3899\/jrheum.150067","article-title":"Effect of urate lowering therapy on renal disease progression in hyperuricemic patients with chronic kidney disease","volume":"42","author":"Kim","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib132","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/annrheumdis-2015-209046","article-title":"Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure","volume":"76","author":"Singh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib133","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10067-014-2806-9","article-title":"Influence of urate-lowering therapies on renal handling of uric acid","volume":"35","author":"Ma","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib134","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ard.41.1.59","article-title":"Allopurinol treatment and its effect on renal function in gout: a controlled study","volume":"41","author":"Gibson","year":"1982","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib135","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2017.01.055_bib136","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","article-title":"Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level","volume":"47","author":"Siu","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib137","first-page":"128","article-title":"Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients","volume":"4","author":"Momeni","year":"2010","journal-title":"Iran J Kidney Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib138","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2215\/CJN.11451210","article-title":"A\u00a0randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function","volume":"6","author":"Kanbay","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib139","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1681\/ASN.2010111185","article-title":"Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease","volume":"22","author":"Kao","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000331453","article-title":"Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial","volume":"35","author":"Shi","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"10.1053\/j.ajkd.2017.01.055_bib141","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib142","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1053\/j.ajkd.2014.11.016","article-title":"Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial","volume":"65","author":"Goicoechea","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib143","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3346\/jkms.2014.29.8.1077","article-title":"Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men","volume":"29","author":"Kim","year":"2014","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1053\/j.ajkd.2017.01.055_bib144","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/cen.12673","article-title":"Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study","volume":"83","author":"Liu","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1053\/j.ajkd.2017.01.055_bib145","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","article-title":"Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial","volume":"66","author":"Sircar","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2017.01.055_bib146","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1007\/s10157-015-1095-1","article-title":"Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial","volume":"19","author":"Tanaka","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib147","first-page":"298","article-title":"Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD)","volume":"66","author":"Sezai","year":"2015","journal-title":"J\u00a0Cardiol"},{"key":"10.1053\/j.ajkd.2017.01.055_bib148","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/ndt\/gft378","article-title":"Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis","volume":"29","author":"Bose","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2017.01.055_bib149","first-page":"vi61","article-title":"Use of allopurinol in slowing the progression of chronic renal disease [abstract]","volume":"22","author":"Sarris","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2017.01.055_bib150","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12882-015-0047-z","article-title":"Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis","volume":"16","author":"Kanji","year":"2015","journal-title":"BMC Nephrol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638617305796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638617305796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:00:20Z","timestamp":1759460420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638617305796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":150,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0272638617305796"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2017.01.055","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Gout and Hyperuricemia in CKD","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2017.01.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}